| Literature DB >> 24837504 |
Reinaldo de Menezes Martins1, Ana Luiza Braz Pavão2, Patrícia Mouta Nunes de Oliveira3, Paulo Roberto Gomes dos Santos4, Sandra Maria D Carvalho5, Renate Mohrdieck6, Alexandre Ribeiro Fernandes7, Helena Keico Sato8, Patricia Mandali de Figueiredo9, Vanessa Dos Reis von Doellinger10, Maria da Luz Fernandes Leal11, Akira Homma12, Maria de Lourdes S Maia10.
Abstract
Neurological adverse events following administration of the 17DD substrain of yellow fever vaccine (YEL-AND) in the Brazilian population are described and analyzed. Based on information obtained from the National Immunization Program through passive surveillance or intensified passive surveillance, from 2007 to 2012, descriptive analysis, national and regional rates of YFV associated neurotropic, neurological autoimmune disease, and reporting rate ratios with their respective 95% confidence intervals were calculated for first time vaccinees stratified on age and year. Sixty-seven neurological cases were found, with the highest rate of neurological adverse events in the age group from 5 to 9 years (2.66 per 100,000 vaccine doses in Rio Grande do Sul state, and 0.83 per 100,000 doses in national analysis). Two cases had a combination of neurotropic and autoimmune features. This is the largest sample of YEL-AND already analyzed. Rates are similar to other recent studies, but on this study the age group from 5 to 9 years of age had the highest risk. As neurological adverse events have in general a good prognosis, they should not contraindicate the use of yellow fever vaccine in face of risk of infection by yellow fever virus.Entities:
Keywords: Adverse event; Neurological autoimmune disease; Neurological disease; Neurotropic disease; Yellow fever vaccine
Mesh:
Substances:
Year: 2014 PMID: 24837504 DOI: 10.1016/j.vaccine.2014.05.003
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641